Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stoccolma | Salute | Ricerca medica e biotecnologica | 18,49 Mrd SEK | -79x | 0,4 | 209,80 SEK | 5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioinvent | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,74 Mrd SEK | -6,7x | 0,21 | 41,60 SEK | 8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hansa Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,72 Mrd SEK | -3,6x | -0,12 | 40 SEK | 2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Egetis Therapeutics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,53 Mrd SEK | -6,4x | -0,38 | 7,10 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Vicore Pharma Holding AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,17 Mrd SEK | -5,2x | -0,24 | 9,27 SEK | 9,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Devyser Diagnostics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,96 Mrd SEK | -26,3x | 1,2 | 120,50 SEK | 1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 26,8% Rialzo | Fai l’upgrade a Pro+ | |
Diamyd Medical | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,77 Mrd SEK | -10,6x | 1,45 | 17,06 SEK | 3,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
XSpray Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,62 Mrd SEK | -5,4x | 1,24 | 44 SEK | 6,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cereno Scientific | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,61 Mrd SEK | -21,5x | 0,37 | 5,72 SEK | 3,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nanoform Finland Plc | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,36 Mrd SEK | -4,9x | 1,61 | 17,36 SEK | 13,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Intellego Technologies AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,17 Mrd SEK | 13,8x | 0,15 | 40,80 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nykode Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 952,86 Mln SEK | -1,9x | 13,98 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Saniona AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 886,13 Mln SEK | -9,1x | -0,41 | 7,88 SEK | -2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 36,8% Rialzo | Fai l’upgrade a Pro+ | |
Abliva AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 693,11 Mln SEK | -5,9x | -0,56 | 0,43 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hamlet Pharma AB | Spotlight | Salute | Ricerca medica e biotecnologica | 603,95 Mln SEK | -15,1x | 0,78 | 3,60 SEK | -3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Mendus AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 427,50 Mln SEK | -2,9x | -0,05 | 8,40 SEK | 7,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Promimic AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 419,79 Mln SEK | -48,5x | 2,2 | 22 SEK | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Initiator Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 393,71 Mln SEK | -23,4x | -0,38 | 7 SEK | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
SynAct Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 370,22 Mln SEK | -2,7x | -0,13 | 9,35 SEK | 4,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medivir | Stoccolma | Salute | Ricerca medica e biotecnologica | 348,84 Mln SEK | -0,1 | 3,15 SEK | 10,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Peptonic Medical | Spotlight | Salute | Ricerca medica e biotecnologica | 345,56 Mln SEK | -0,4x | -0,01 | 0,004 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Oncopeptides | Stoccolma | Salute | Ricerca medica e biotecnologica | 339,56 Mln SEK | -0,8x | -0,04 | 1,58 SEK | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cantargia AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 312,27 Mln SEK | -1,6x | -0,04 | 1,70 SEK | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alzinova | Stoccolma | Salute | Ricerca medica e biotecnologica | 303,16 Mln SEK | -10x | -0,67 | 3,42 SEK | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Ascelia Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 280,63 Mln SEK | -2x | -0,07 | 3,07 SEK | 5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Xbrane Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 275,31 Mln SEK | -0,4x | 0,18 SEK | 10,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Curasight AS | Spotlight | Salute | Ricerca medica e biotecnologica | 271,49 Mln SEK | -7,2x | 0,39 | 13,62 SEK | 3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Guard Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 248,36 Mln SEK | -2,4x | -0,07 | 20,20 SEK | 4,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Annexin Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 235,04 Mln SEK | -3,3x | -0,1 | 0,45 SEK | 4,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
NextCell Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 207,58 Mln SEK | -0,46 | 2,54 SEK | -10,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |